title: Transfusion-related acute lung injury: a clinical review.
abstract: Three decades ago, transfusion-related acute lung injury (TRALI) was considered a rare complication of transfusion medicine. Nowadays, the US Food and Drug Administration acknowledge the syndrome as the leading cause of transfusion-related mortality. Understanding of the pathogenesis of TRALI has resulted in the design of preventive strategies from a blood-bank perspective. A major breakthrough in efforts to reduce the incidence of TRALI has been to exclude female donors of products with high plasma volume, resulting in a decrease of roughly two-thirds in incidence. However, this strategy has not completely eradicated the complication. In the past few years, research has identified patient-related risk factors for the onset of TRALI, which have empowered physicians to take an individualised approach to patients who need transfusion.
authors: Department of Intensive Care Medicine, Academic Medical Centre, Amsterdam, Netherlands.
authors: Alexander P J
authors: AP
authors: Vlaar
authors: Nicole P
authors: NP
authors: Juffermans
mesh_terms: D055371:Acute Lung Injury / Q000175:diagnosis / Q000209:etiology*; D000917:Antibody Formation / Q000502:physiology; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D018375:Neutrophil Activation / Q000276:immunology / Q000502:physiology; D009504:Neutrophils / Q000276:immunology; D011654:Pulmonary Edema / Q000209:etiology; D013997:Time Factors; D065227:Transfusion Reaction
chemical_list: D016207:Cytokines